Advantages of standardizing diabetes treatments

July 8, 2014, Investigación y Desarrollo

Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, used to set the tone in the control of the disease and how to apply a better therapy, depending on the physical condition of the person.

All guides propose that from the moment diabetes is diagnosed, the patient should diet combined with exercise, and start taking , which is the "standard prescription" of all international and national guidelines, said Rutila Castañeda Limones endocrinology specialist and researcher at the "Mexico Center for Clinical Research".

In Mexico, the guides are used in all public and private medical institutions, the Mexican Social Security Institute (IMSS) has the lead, although the Mexican Official Standard is supported by the proposals of the international organizations, which are based on European and American standards.

Metformin helps the patient lose weight, improves the biological effect of the administered insulin, reduces cardiovascular risk and osteoporosis, plus it's the cheapest drug for diabetics on the market.

As a second option therapeutic, medical guides explain that if this drug were to decompensate the patient a combined treatment should be given, taking metformin as a base, since virtually all metabolic alterations caused by diabetes are covered.

The advantage of metformin is that it can be combined with other drugs, such as GLP-1 or insulin. Potentiating the treatment and minimizing side effects.

Castañeda Limones said that although there are many options on the market for metformin, not all have the same response in , so the doctor and patient must give timely follow ups.

There are options for quick and prolonged release, which will be administered according to patient characteristics. For example, using extended release metformin as the presentation by Merck pharmaceuticals, which was recently launched in Mexico, helps to reduce side effects in the patient, explained the specialist in endocrinology.

Medical guides focus on patient characteristics, according to age, family conditions, if you have a support network, or associated diseases. Endocrinologists should determine the best possible treatment.

"If a patient has hypertension, obesity, overweight, cardiovascular damage, there is greater difficulty in achieving adequate treatment and is therefore more difficult to take it to the goals of excellence," said the specialist in endocrinology and nutrition.

Explore further: Study reverses current thought on treatment of cirrhosis

Related Stories

Study reverses current thought on treatment of cirrhosis

June 19, 2014
Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved ...

African-Americans respond better to first-line diabetes drug than whites

June 12, 2014
African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine ...

Added benefit of the fixed combination of dapagliflozin and metformin is not proven

May 15, 2014
The fixed combination of the drugs dapagliflozin and metformin (trade name: Xigduo) has been approved since January 2014 for adults with type 2 diabetes in whom diet and exercise do not provide adequate glycaemic control. ...

Metformin usually adequate for control of gestational diabetes

August 18, 2013
(HealthDay)—Among women with gestational diabetes mellitus, those receiving metformin achieve lower mean glucose levels compared with those receiving insulin, but some require supplemental insulin therapy, according to ...

Diabetes patients should have more voice in treatment: experts

October 2, 2012
(HealthDay)—New guidelines meant to provide type 2 diabetes patients with truly individualized care have been issued by the American Diabetes Association and the European Association for the Study of Diabetes.

Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven

June 17, 2014
Canagliflozin (trade name: Invokana) has been approved since November 2013 as monotherapy and in various combination therapies for adults with type 2 diabetes mellitus when diet and exercise alone do not provide adequate ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.